Eletriptan: a review and new perspectives

References

• Headache Classification Committee of the International Headache Society. The International Classification of Headache Disorders: (2nd Edition). Cephalalgia24(Suppl. 1), 9–160 (2004).
   PubMed Web of Science ®Google Scholar
• Lipton RB, Bigal ME. Migraine: epidemiology, impact, and risk factors for progression. Headache45(Suppl. 1), S3–S13 (2005).
   Google Scholar
• Lyngberg AC, Rasmussen BK, Jorgensen T, Jensen R: Incidence of primary headache: a Danish epidemiologic follow-up study. Am. J. Epidemiol.161(11), 1066–1073 (2005).
   PubMed Web of Science ®Google Scholar
• Hu XH, Markson LE, Lipton RB, Stewart WF, Berger ML. Burden of migraine in the US: disability and economic costs. Arch. Intern. Med.159, 813–818 (1999).
   PubMed Web of Science ®Google Scholar
• Stewart WF, Ricci JA, Chee E, Morganstein D, Lipton R. Lost productive time and cost due to common pain conditions in the US workforce. JAMA290(18), 2443–2454 (2003).
   PubMed Web of Science ®Google Scholar
• Goadsby PJ. The pharmacology of headache. Prog. Neurobiol.62(5), 509–525 (2000).
   PubMed Web of Science ®Google Scholar
• Silberstein SD. Practice parameter: evidence-based guidelines for migraine headache (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology55(6), 754–762 (2000).
   PubMed Web of Science ®Google Scholar
• Diener HC, Jansen JP, Reches A, Pascual J, Pitei D. Efficacy, tolerability and safety of oral eletriptan and ergotamine plus caffeine (Cafergot®) in the acute treatment of migraine: a multicentre, randomized, double-blind, placebo-controlled comparison. Eur. Neurol.47(2), 99–107 (2002).
   PubMed Web of Science ®Google Scholar
• Mathew NT, Hettiarachchi J, Alderman J. Tolerability and safety of eletriptan in the treatment of migraine: a comprehensive review. Headache43(9), 962–974 (2003).
   PubMed Web of Science ®Google Scholar
• Napier C, Stewart M, Melrose H, Hopkins B, McHarg A, Wallis R. Characterisation of the 5-HT receptor binding profile of eletriptan and kinetics of [3H]eletriptan binding at human 5-HT1B and 5-HT1D receptors. Eur. J. Pharmacol.368(2–3), 259–268 (1999).
   PubMed Web of Science ®Google Scholar
• Tfelt-Hansen P, De Vries P, Saxena PR. Triptans in migraine: a comparative review of pharmacology, pharmacokinetics and efficacy. Drugs60(6), 1259–1287 (2000).
   PubMed Web of Science ®Google Scholar
• Jhee SS, Shiovitz T, Crawford AW, Cutler NR. Pharmacokinetics and pharmacodynamics of the triptan antimigraine agents: a comparative review. Clin. Pharmacokinet.40(3), 189–205 (2001).
   PubMed Web of Science ®Google Scholar
• Maassen Van Den Brink A, van den Broek RW, de Vries R, Bogers AJ, Avezaat CJ, Saxena PR. Craniovascular selectivity of eletriptan and sumatriptan in human isolated blood vessels. Neurology55(10), 1524–1530 (2000).
   PubMed Web of Science ®Google Scholar
• Gupta P, Butler P, Shepperson NB, McHarg A. The in vivo pharmacological profile of eletriptan (UK-116,044): a potent and novel 5-HT(1B/1D) receptor agonist. Eur. J. Pharmacol.398(1), 73–81 (2000).
   PubMed Web of Science ®Google Scholar
• Goldstein JA, Massey KD, Kirby S et al. Effect of high-dose intravenous eletriptan on coronary artery diameter. Cephalalgia24(7), 515–521 (2004).
   PubMed Web of Science ®Google Scholar
• Knyihar-Csillik E, Tajti J, Csillik AE, Chadaide Z, Mihaly A, Vecsei L. Effects of eletriptan on the peptidergic innervation of the cerebral dura mater and trigeminal ganglion, and on the expression of c-fos and c-jun in the trigeminal complex of the rat in an experimental migraine model. Eur. J. Neurosci.12(11), 3991–4002 (2000).
   PubMed Web of Science ®Google Scholar
• Hoskin KL, Lambert GA, Donaldson C, Zagami AS. The 5-hydroxytryptamine1B/ 1D/1F receptor agonists eletriptan and naratriptan inhibit trigeminovascular input to the nucleus tractus solitarius in the cat. Brain Res.998(1), 91–99 (2004).
   PubMed Web of Science ®Google Scholar
• Milton KA, Scott NR, Allen MJ et al.. Pharmacokinetics, pharmacodynamics, and safety of the 5-HT 1B/1D agonist eletriptan following intravenous and oral administration. J Clin. Pharmacol.42, 528–539 (2002).
   PubMed Web of Science ®Google Scholar
• Shah AK, Harris SC, Greenhalgh C, Morganroth J. The pharmacokinetics and safety of single escalating oral doses of eletriptan. J. Clin. Pharmacol.42, 520–527 (2002).
   PubMed Web of Science ®Google Scholar
• Evans DC, O’Connor D, Lake BG, Evers R, Allen C, Hargreaves R. Eletriptan metabolism by human hepatic CYP450 enzymes and transport by human P-glycoprotein. Drug Metab. Dispos.31(7), 861–869 (2003).
   PubMed Web of Science ®Google Scholar
• Shah AK, Laboy-Goral L, Scott N, Morse T, Apseloff G. Pharmacokinetics and safety of oral eletriptan during different phases of the menstrual cycle in healthy volunteers. J. Clin. Pharmacol.41(12), 1339–1344 (2001).
   PubMed Web of Science ®Google Scholar
• Oldman AD, Smith LA, McQuay HJ, Moore RA. Pharmacological treatments for acute migraine: quantitative systematic review. Pain97(3), 247–257 (2002).
   PubMed Web of Science ®Google Scholar
• Ferrari MD, Roon KI, Lipton RB, Goadsby PJ. Oral triptans (serotonin 5-HT(1B/1D) agonists) in acute migraine treatment: a meta-analysis of 53 trials. Lancet358(9294), 1668–1675 (2001).
   PubMed Web of Science ®Google Scholar
• Smith LA, Oldman AD, McQuay HJ, Moore RA. Eletriptan for acute migraine. Cochrane Database Syst. Rev. (3), CD003224 (2001).
   Google Scholar
• Salonen R, Kori S, Scott A, Richardson MS. Encapsulated sumatriptan is not bioequivalent to commercial sumatriptan. Headache43(8), 923–924 (2003).
   PubMed Web of Science ®Google Scholar
• Mandema JW, Cox E, Alderman J. Therapeutic benefit of eletriptan compared to sumatriptan for the acute relief of migraine pain results of a model-based meta-analysis that accounts for encapsulation. Cephalalgia25(9),715–725 (2005).
   PubMed Web of Science ®Google Scholar
• Sheftell F, Ryan R, Pitman V. Eletriptan Steering Committee. Efficacy, safety, and tolerability of oral eletriptan for treatment of acute migraine: a multicenter, double-blind, placebo-controlled study conducted in the United States. Headache43(3), 202–213 (2003).
   PubMed Web of Science ®Google Scholar
• Stark R, Dahlof C, Haughie S, Hettiarachchi J; Eletriptan Steering Committee. Efficacy, safety and tolerability of oral eletriptan in the acute treatment of migraine: results of a Phase III, multicentre, placebo-controlled study across three attacks. Cephalalgia22(1), 23–32 (2002).
   PubMed Web of Science ®Google Scholar
• Eletriptan Steering Committee in Japan. Efficacy and safety of eletriptan 20 mg, 4 mg and 80 mg in Japanese migraineurs. Cephalalgia22(6), 416–423 (2002).
   PubMed Web of Science ®Google Scholar
• Wells NE, Steiner TJ. Effectiveness of eletriptan in reducing time loss caused by migraine attacks. Pharmacoeconomics18(6), 557–566 (2000).
   PubMed Web of Science ®Google Scholar
• Goadsby PJ, Ferrari MD, Olesen J, Stovner LJ, Senard JM. Eletriptan in acute migraine: a double-blind, placebo-controlled comparison to sumatriptan. Neurology54(1), 156–163 (2000).
   PubMed Web of Science ®Google Scholar
• Sandrini G, Farkkila M, Burgess G, Forster E, Haughie S. Eletriptan Steering Committee. Eletriptan vs sumatriptan: a double-blind, placebo-controlled, multiple migraine attack study. Neurology59(8), 1210–1217 (2002).
   PubMed Web of Science ®Google Scholar
• Mathew NT, Schoenen J, Winner P, Muirhead N, Sikes CR. Comparative efficacy of eletriptan 40 mg versus sumatriptan 100 mg. Headache43(3), 214–222 (2003).
   PubMed Web of Science ®Google Scholar
• Diener HC, Ryan R, Sun W, Hettiarachchi J. The 40-mg dose of eletriptan: comparative efficacy and tolerability versus sumatriptan 100 mg. Eur. J. Neurol.11(2), 125–134 (2004).
   PubMed Web of Science ®Google Scholar
• Schoenen J, Pascual J, Rasmussen S, Sun W, Sikes C, Hettiarachchi J. Patient preference for eletriptan 80 mg versus subcutaneous sumatriptan 6 mg: results of a crossover study in patients who have recently used subcutaneous sumatriptan. Eur. J. Neurol.12(2), 108–117 (2005).
   PubMed Web of Science ®Google Scholar
• Färkkilä M, Olesen J, Dahlöf C et al. Eletriptan for the treatment of migraine in patients with previous poor response or tolerance to oral sumatriptan. Cephalalgia23, 198–203 (2003).
   Google Scholar
• Steiner TJ, Diener HC, MacGregor EA, Schoenen J, Muirhead N, Sikes CR. Comparative efficacy of eletriptan and zolmitriptan in the acute treatment of migraine. Cephalalgia23, 942–952 (2003).
   PubMed Web of Science ®Google Scholar
• Garcia-Ramos G, MacGregor EA, Hilliard B, Bordini CA, Leston J, Hettiarachchi J. Comparative efficacy of eletriptan versus naratriptan in the acute treatment of migraine. Cephalalgia23, 869–876 (2003).
   PubMed Web of Science ®Google Scholar
• Lainez MJ, Evers S, Kinge E et al. Preference for rizatriptan 10-mg wafer vs. eletriptan 40-mg tablet for acute treatment of migraine. Cephalalgia26(3), 246–256 (2006).
   PubMed Web of Science ®Google Scholar
• Newman CM, Starkey I, Buller N et al. Effects of sumatriptan and eletriptan on diseased epicardial coronary arteries. Eur. J. Clin. Pharmacol.61(10), 733–742 (2005).
   PubMed Web of Science ®Google Scholar
• Perfetto EM, Weis KA, Mullins CD, Subedi P, Healey PJ Sr. An economic evaluation of triptan products for migraine. Value Health8(6), 647–655 (2005).
   PubMed Web of Science ®Google Scholar
• Chia Y-C, Lim S-H, Wang S-J, Cheong YM, Denaro J, Hettiarachchi J. Efficacy of eletriptan in migraineurs with persistent poor response to nonsteroidal anti-inflammatories. Headache43, 984–990 (2003).
   PubMed Web of Science ®Google Scholar
• Martin VT, Loder E, Taylor K, Almas M, Hilliard B. Eletriptan treatment of migraine in patients switching from barbiturate-containing analgesics: results from a multiple-attack study. Cephalalgia25(9), 726–734 (2005).
   PubMed Web of Science ®Google Scholar
• Pascual J. Clinical benefits of early triptan therapy for migraine. Headache42 (Suppl. 1), S10–S17 (2002).
   PubMedGoogle Scholar
• Brandes JL, Kudrow D, Cady R, Tiseo PJ, Sun W, Sikes CR. Eletriptan in the early treatment of acute migraine: influence of pain intensity and time of dosing. Cephalalgia25, 735–742 (2005).
   PubMed Web of Science ®Google Scholar
• Newman L, Mannix LK, Landy S et al. Naratriptan as short-term prophylaxis of menstrually associated migraine: a randomized, double-blind, placebo-controlled study. Headache41(3), 248–256 (2001).
   PubMed Web of Science ®Google Scholar
• Silberstein SD, Elkind AH, Schreiber C, Keywood C. A randomized trial of frovatriptan for the intermittent prevention of menstrual migraine. Neurology63(2), 261–269 (2004).
   PubMed Web of Science ®Google Scholar
• van Vliet JA, Bahra A, Martin V et al. Intranasal sumatriptan in cluster headache: randomized placebo-controlled double-blind study. Neurology60(4), 630–633 (2003).
   PubMed Web of Science ®Google Scholar
• Bahra A, Gawel MJ, Hardebo JE, Millson D, Breen SA, Goadsby PJ. Oral zolmitriptan is effective in the acute treatment of cluster headache. Neurology54(9), 1832–1839 (2000).
   PubMed Web of Science ®Google Scholar
• Mulder LJ, Spierings EL. Naratriptan in the preventive treatment of cluster headache. Cephalalgia22(10), 815–817 (2002).
   PubMed Web of Science ®Google Scholar
• Zebenholzer K, Wober C, Vigl M, Wessely P. Eletriptan for the short-term prophylaxis of cluster headache. Headache44(4), 361–364 (2004).
   PubMed Web of Science ®Google Scholar
• Winner P. Triptans for migraine management in adolescents. Headache42(7), 675–679 (2002).
   Google Scholar
• Pitman V. Efficacy, safety and tolerability of oral eletriptan (40mg) for the treatment of acute migraine in adolescents (12–17years). Abstract in 42nd Annual Scientific Meeting The American Headache Society. Montreal, Quebec, Canada, June 23–25 (2000).
   Google Scholar
• Damen L, Bruijn JK, Verhagen AP, Berger MY, Passchier J, Koes BW. Symptomatic treatment of migraine in children. A systematic review of medication trials. Pediatric116(2), E295–E302 (2005).
   Google Scholar
• Jakubowski M, Levy D, Goor-Aryeh I, Collins B, Bajwa Z, Burstein R. Terminating migraine with allodynia and ongoing central sensitization using parenteral administration of COX1/COX2 inhibitors. Headache45(7), 850–861 (2005).
   PubMed Web of Science ®Google Scholar